

CD8⁺ cytolytic T cell clones derived against the *Plasmodium yoelii* circumsporozoite protein protect against malaria

Mauricio M. Rodrigues, Anne-Sophie Cordey¹, Gladys Arreaza, Giampetro Corradin¹, Pedro Romero², Janet L. Maryanski², Ruth S. Nussenzweig, and Fidel Zavala

Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY 10010, USA

¹Institute of Biochemistry, University of Lausanne, and ²Ludwig Institute for Cancer Research, Lausanne Branch, 1066 Epalinges, Switzerland

Key words: cytotoxic epitopes, malaria immunity, CS protein

Abstract

Immunization of BALB/c mice with radiation-attenuated *Plasmodium yoelii* sporozoites induces cytotoxic T lymphocytes (CTL) specific for an epitope located within the amino acid sequence 277–288 of the *P. yoelii* circumsporozoite (CS) protein. Several CD8⁺ CTL clones were derived from the spleen cells of sporozoite-immunized mice, all displaying an apparently identical epitope specificity. All the clones induced high levels of cytolysis *in vitro* upon exposure to peptide-incubated MHC-compatible target cells. The adoptive transfer of two of these clones conferred complete protection against sporozoite challenge to naive mice. This protection is species and stage specific. Using *P. yoelii* specific ribosomal RNA probes to monitor the *in vivo* effects of the CTL clones, we found that their target was the intrahepatocytic stage of the parasite. The protective clones completely inhibited the development of the liver stages of *P. yoelii*. Some CTL clones were only partially inhibitory *in vivo*, while others failed completely to alter liver stage development and to confer any detectable degree of protection. The elucidation of the effector mechanism of this CTL mediated protection against rodent malaria should facilitate the design of an effective malaria vaccine. From a broader perspective this model may provide further insight into the mechanism(s) of CTL mediated killing of intracellular non-viral pathogens in general.

Introduction

Protective immunity against rodent, simian and human malaria can be achieved by immunization with radiation-attenuated sporozoites (1). This protection appears to be mediated by a combination of humoral and T-cell mediated mechanisms (2,3). The extent to which any of these individual immune mechanisms can confer protection, in the absence of the others, remains to be determined.

Epitopes located within the circumsporozoite (CS) protein that are recognized by CD8⁺ cytolytic T lymphocytes (CTL) have been defined for several species of *Plasmodia* (3–6). Immunization of BALB/c mice with irradiated *Plasmodium berghei* sporozoites induces CD8⁺ CTL which recognize a synthetic peptide comprising amino acids 249–260 (NDDSYPSAEKI) of its CS protein (3). Immunization with irradiated *Plasmodium yoelii* sporozoites of BALB/c mice also induces CD8⁺ CTL, which recognize an epitope contained in a peptide with a sequence

(*P. yoelii* CS 277–288, NEDSYVPSAEQI) highly homologous to that of the *P. berghei* CTL epitope. Both of these CS peptides are presented to T cells in the context of the major histocompatibility complex (MHC) H-2 k^d molecule (6). Another study (5) defined a similar, overlapping *P. yoelii* CS epitope (CS 281–296).

It has been established that the adoptive transfer of cloned CD8⁺ CTLs specific for the *P. berghei* CS epitope can confer complete protection against sporozoite-induced infection (3). However, it has been suggested that CD8⁺ T cells against the *P. yoelii* CS protein may not have a similar protective role (5). The availability of cloned CD8⁺ CTL, specific for the *P. yoelii* cytotoxic CS epitope, did permit us to establish the broader validity of the protective role of anti-CS CD8⁺ CTL in rodent malaria and, also, determine their specificity. Using a recently described method for measuring plasmodial ribosomal RNA

sequences in infected mouse liver, we evaluated quantitatively the protective *in vivo* activity of the CTL clones.

Methods

Parasites and animals

Plasmodium yoelii (17X NL strain) and *P. berghei* (NK 65 strain) were maintained by repeated cyclic passage of the parasites through *Anopheles stephensi* mosquitoes, and BALB/c mice or hamsters, respectively. BALB/c mice and hamsters were purchased from Jackson Laboratories, Bar Harbor, ME and from Charles River Laboratories, Wilmington, MA, respectively. Sporozoites were collected by dissecting the mosquito salivary glands in medium 199, ~2 weeks after the infective blood meal.

Female BALB/c mice aged 4–8 weeks were used for the immunological studies. Mice were challenged intravenously with the indicated dose of viable sporozoites. Their parasitemia was monitored daily by peripheral blood smears obtained from the 3rd to the 10th day after challenge.

Peptides

Two peptides containing the CTL epitopes of the CS protein of *P. berghei* (Pb 249–260 NDDSYIPSAEKI) and of *P. yoelii* (Py 277–288 NDESYVPSAEQI) were synthesized as described (3).

Cell culture

As culture medium we used DMEM – high glucose (Grand Island Biological Co., Long Island, NY) supplemented with 0.2 g/l of L-arginine (Calbiochem Co., La Jolla, CA), 0.036 g/l of L-asparagine (GIBCO), 10 mM HEPES, 2 mM L-glutamine, 5×10^{-5} M 2-mercaptoethanol, 10% fetal calf serum (Hyclone, Logan, Utah) and 1.5–2% of T cell growth factor medium, derived from phorbol myristate-acetate activated EL-4 cells (7). The cultures were maintained at 37°C in an atmosphere containing 5% CO₂.

Stimulation and cloning of the cytotoxic T lymphocytes (CTL)

Two BALB/c mice were injected four times, *i.v.*, with 10⁵ radiation-attenuated (15×10^3 rads) *P. yoelii* sporozoites, every 15 days. Two weeks after the last injection, immune spleen cells were stimulated in culture with P815 cells, that had been pulsed with peptide Py 277–288, as previously described (6). After the third cycle of *in vitro* stimulation, cells were cloned, 0.5–1000 cells per well, in the presence of irradiated spleen cells and peptide pulsed P815 cells, as previously described (8).

Cells were also cloned directly from immune spleen cells using 300–10,000 spleen cells per well. Once established, the clones (0.125×10^6 per ml) were re-stimulated weekly with irradiated feeder cells (2.5×10^6 per ml), and irradiated P815 cells (1.25×10^5 per ml) pulsed with 1 μM of either peptide Py 277–288 or Pb 249–260. Four days later, and after the addition of an equal volume of medium, the cultures were divided and grown under the same conditions for 2–3 more days.

Adoptive transfer of CTL clones

CTL clones were harvested 6–7 days after re-stimulation with peptide-pulsed target cells and feeder cells. The desired number of cells from the CTL clones or spleens were centrifuged and resuspended in DMEM medium containing 2×10^3 units per ml

of human recombinant interleukin 2 (IL-2) (kindly provided by Hoffmann-LaRoche), immediately before transfer. A total volume of 0.5 ml of the cell suspension or IL-2 alone was injected *i.v.* into each mouse. All mice were challenged with sporozoites, 16–20 h after the cell transfer, unless otherwise indicated. These mice also received 10³ units of human recombinant IL-2, 1 day after the challenge. In some experiments the mice were also treated with mouse monoclonal antibody DB-1, which neutralizes murine interferon gamma (IFN-γ) (9), or hamster monoclonal antibody TN3.19.12, anti-murine tumor necrosis factor (TNF) (10). These antibodies were injected 2 h before the CTL clones. In these experiments, the mice were challenged 5–6 h after the injection of the T cells.

Quantification of *P. yoelii* rRNA in the liver of infected mice

Total RNA was isolated from the livers of mice killed 42 h after they had been injected with 2×10^5 sporozoites of *P. yoelii*. At this time, *i.e.* 42 h after challenge, the intra-hepatocytic parasites (schizonts) have undergone maximal nuclear division and growth. The sporozoite dose was selected based on the finding that it consistently generates a strong signal, permitting the measurement of *P. yoelii* rRNA in the livers of control animals (11). Details of the method of isolation of RNA, the composition of the oligonucleotide probes specific for *P. yoelii* ribosomal RNA, and the hybridization procedure have been described elsewhere (11). Briefly, RNA was prepared by the method of Chomczynski and Sacchi (12). One-tenth of the whole liver RNA was precipitated with isopropanol. The RNA pellet was dissolved in 10 mM Tris–HCl pH 8.0, 1 mM EDTA, denatured at 65°C in $20 \times$ SSC (1 × SSC contains 150 mM NaCl, 15 mM Na citrate):37% formaldehyde (1:1). This solution was diluted 45 times and 0.2 ml were blotted onto nylon membranes. The RNA was fixed to the filters by UV crosslinking. Hybridization was performed overnight in $5 \times$ SSPE (1 × SSPE contains 180 mM NaCl, 10 mM Na phosphate, 1 mM EDTA, pH 7.7), 1% sodium dodecyl sulfate (SDS) and 500 μg/ml heparin at 42°C, containing several oligonucleotide probes labeled with ³²P (10^6 c.p.m./ml; specific activity $>2 \times 10^8$ c.p.m./μg). Filters were washed twice in $6 \times$ SSC + 0.1% SDS and once with 1 × SSC + SDS, at room temperature for 15 min. The membranes were dried, the spots on the filters were cut out and the radioactivity measured in a liquid scintillation counter. A standard curve, for comparison purposes, was prepared using purified RNA from *P. yoelii* infected erythrocytes, and blotted under the same conditions. The minimum amount of rRNA that this assay can detect is 1 ng per sample.

Chromium release assay

For this *in vitro* cytotoxicity assay we used P815, a histocompatible (H-2^d) cell line, standardly used as target cell, labelled with 250 μCi of ⁵¹Cr (ICN Biomedicals, Irvine, CA). After washing, 2×10^3 cells per well were cultured with 10⁴ CTL, in the presence of the desired concentration of the peptide of choice. After 4 h at 37°C, the supernatants were collected with the aid of a semi-automatic harvester (Skatron, Sterling, VA). The results are expressed as the mean values obtained from duplicate cultures. The percentage of specific lysis was calculated as follows: $\frac{\text{experimental} - \text{spontaneous release c.p.m.}}{\text{total} - \text{spontaneous release}} \times 100$.




Fig. 1. Specificity of the *in vitro* lytic activity of CD8⁺ anti-CS clones. CTL clones (YB8, YA15, YA23 and YA26), generated by immunization with irradiated *P. yoelii* sporozoites (panels A–D) or *P. berghei* sporozoites (clone CS C7, panel E) were incubated with ⁵¹Cr-labelled P815 target cells, in the presence of various concentrations of the *P. yoelii* peptide 277–288 (●) or *P. berghei* peptide 246–260 (○). The effector to target ratio (E/T) used in these experiments was 5:1. The release of ⁵¹Cr was measured after 4 h of incubation.

Results

Cytotoxic anti-P. yoelii CD8⁺ T cell clones protect against a challenge with *P. yoelii* sporozoites

Five CTL lines were obtained after cloning cells from one immune spleen (YA) that had been stimulated in mass culture for three weekly cycles: YA11, YA15, YA20, YA23, and YA26. Two others (YA2 and YB8) were cloned directly from immune spleen cells, i.e. without first undergoing *in vitro* stimulation. All these CTL clones recognize a synthetic peptide comprising the amino acid sequence 277–288 of the *P. yoelii* CS protein. As shown in Fig. 1 (A to D), these CTL clones lyse the target cells in the presence of the *P. yoelii* peptide 277–288, but do not recognize the cytotoxic epitope of *P. berghei* (peptide 249–260). In contrast, the CTL clone CS.C7 (3), derived from *P. berghei* immunized mice, recognizes the *P. berghei* CTL epitope and also displays a low, but significant, cross-reactivity with the *P. yoelii* epitope (Fig. 1E). All these clones express CD3 and CD8, but not CD4 surface markers and are restricted by H-2k^d (6).

To investigate the *in vivo* anti-plasmodial activity of the CD8⁺ T cell clones, a series of adoptive transfer experiments were performed in naive mice which, 20 h later, were challenged with

Table 1. Effect of adoptive transfer of CTL clones on the outcome of a challenge with *Plasmodium yoelii* sporozoites

CTL clone transferred	No. of cells (× 10 ⁶)	Protected mice/total challenged ^a	Percentage of protection
YA23	32	5/5	100
YA26	32	5/5	100
YB8	28	0/5	0
YA15	90	0/3	0
Spleen cells	31	0/5	0
YA26	25–30	7/10	70
None	–	0/10	0

^aAll mice were challenged *i.v.* with 100 *P. yoelii* sporozoites. The protected animals remained negative, while all the control mice developed parasitemia.

viable *P. yoelii* sporozoites. As shown in Table 1, all the mice which received the cytotoxic clones YA23 and YA26 were protected, i.e. failed to develop parasitemia after sporozoite challenge. In contrast, adoptive transfer of CTL clones YB8 and

YA15, which appear to have the same epitope specificity as YA23 and YA26, failed to confer protection, even when as many as 9×10^7 cells of clone YA15 were transferred to each mouse.

The protection conferred by clones YA23 and YA26 did depend on the size of the sporozoite challenge. Protection was consistently achieved when the mice were challenged with 100 *P. yoelii* sporozoites, which resulted in 100% infection in the control group. The number of sporozoites used for challenge represents five times the minimum dose required to achieve infection of 100% of normal BALB/c mice (data not shown). When the challenge dose consisted of 1000 or more sporozoites, the experimental animals were no longer protected. They developed parasitemia, usually 1 day later than the controls (data not shown). When blood stages of *P. yoelii* were used to challenge the mice which had received the clone YA26, no inhibition of parasite development occurred, indicating that the protective activity of the CTL clones is stage specific (data not shown).

While the protective CTL clones inhibited parasite development when transferred into mice 20 h before their challenge with sporozoites, we observed a similar degree of protection when the CTL were transferred after sporozoite invasion of the hepatocytes has taken place (13). As seen in Table 2, when the anti-*P. yoelii* clone (YA26) was transferred 3 h after challenge with *P. yoelii* sporozoites, it conferred full protection to 73% of the mice. This same clone, transferred 20 h before challenge, conferred protection to 80% of the mice. Similar results were obtained with the anti-*P. berghei* CTL clone, CS.C7, which protected all the mice, regardless of whether it was transferred before or after sporozoite challenge (Table 2).

Species-specificity of the protection mediated by anti-*P. yoelii* and anti-*P. berghei* CTL clones

The *in vitro* results did indicate that the CTL clones YB8, YA15, YA23, and YA26 (anti-*P. yoelii*) do not recognize the *P. berghei* epitope (Fig. 1A–D). As for the protective anti-*P. berghei* clone, CS.C7, it displays *in vitro*, a weak cross-reactivity with the *P. yoelii* epitope (Fig. 1E).

To characterize further the species-specificity of the protection

mediated by the anti-*P. yoelii* CTL clones, we performed a series of cross-protection experiments. When the CTL clone YA26 (anti-*P. yoelii*) was transferred to mice and these were challenged with *P. yoelii* sporozoites, 90% of the mice were protected, i.e. did not develop parasitemia. In contrast, 80% of the mice which received the same YA26 clone developed parasitemia after they were challenged with *P. berghei* sporozoites (Table 3). Conversely, when mice were injected with the anti-*P. berghei* clone, CS.C7, 100% protection was obtained in the group of mice challenged with *P. berghei* sporozoites, while no protection was observed when the challenge consisted of *P. yoelii* sporozoites (Table 3). All control mice injected with *P. yoelii* and more than 90% of those infected with *P. berghei* sporozoites developed parasitemia.

CTL clones inhibit the development of the liver stages of *P. yoelii*

To gain further and more quantitative insight into the inhibitory effect of these CTL clones on the development of liver stages of *P. yoelii*, we measured the amount of parasite-specific rRNA present in the liver of mice which had received CTL clones and were subsequently injected with *P. yoelii* sporozoites. The livers of several mice were excised 42 h after sporozoite challenge and the total RNA from each mouse liver was partially purified. The amount of parasite rRNA was determined on the basis of a dot-hybridization assay, using parasite-specific ribosomal oligonucleotide probes, as described elsewhere (11).

We found that mice which had received 2.5×10^7 cells of the protective clone YA26, and had been challenged with 2×10^5 *P. yoelii* sporozoites, had very little or no detectable parasite rRNA in their livers. In contrast, the levels of parasite rRNA present in the livers of mice which had received the non-protective clone YA15 were comparable to those present in control mice, injected with parasites, but not with cytotoxic T cell clones (Fig. 2A). Identical results were obtained when the transfer of CTL clones was performed 20 h after sporozoite challenge (data not shown).

Noteworthy was the finding that mice injected with clone YB8, considered to be non-protective on the basis of the parasitemia which the mice developed after cell transfer and challenge

Table 2. Protective effect of the adoptive transfer of CTL clones performed prior to and after sporozoite challenge

CTL clone transferred	Hours before (–) or after (+) challenge	Sporozoite species	Protected mice/total challenged ^a (% of protection)
YA26	–20	<i>P. yoelii</i>	8/10 (80) ^b
YA26	+3	<i>P. yoelii</i>	11/15 (73)
–	–	<i>P. yoelii</i>	0/10 (0)
CS.C7	–20	<i>P. berghei</i>	10/10 (100) ^c
CS.C7	+3	<i>P. berghei</i>	9/9 (100)
–	–	<i>P. berghei</i>	1/12 (8)

^aMice were challenged with 100 sporozoites of *P. yoelii* or 10^4 of *P. berghei* sporozoites. These doses represent five times the minimum amount of sporozoites to produce patent parasitemia in BALB/c mice. All *P. yoelii* controls and 11 of the 12 *P. berghei* control mice developed patent infections. None of the 'protected' mice developed parasitemia.

^b $0.5–2.5 \times 10^7$ T cells were transferred per mouse. Combined results of two experiments.

^c 2×10^7 T cells were transferred per mouse.

Table 3. Effect of the adoptive of CTL clones YA26 and CS.C7 on the outcome of challenge with either *P. yoelii* or *P. berghei* sporozoites

CTL clones transferred ^a	Sporozoite challenge	Protected mice/total challenged ^b	Percentage of protection
YA26	<i>P. yoelii</i>	9/10	90
CS.C7	<i>P. yoelii</i>	0/10	0
None	<i>P. yoelii</i>	0/5	0
YA26	<i>P. berghei</i>	4/20 ^c	20
CS.C7	<i>P. berghei</i>	19/20	95
None	<i>P. berghei</i>	0/20	0

^a $2–4 \times 10^7$ of CTL clone YA26, and $2–3 \times 10^7$ cells of CTL clones CS.C7 were transferred per mouse.

^bAll mice were challenged with 10^4 *P. yoelii* or 10^4 *P. berghei* sporozoites. These doses represent five times the minimum amount of sporozoites to produce patent parasitemia in BALB/c mice. All the control mice developed patent infections, while the protected mice remained negative.

^cCombined results of four experiments.

(Table 1), showed a 59% reduction of the amount of *P. yoelii* rRNA in the liver. The adoptive transfer of CTL clone CS.B83, which is specific for the *P. berghei* epitope and does not cross-react *in vitro* with the *P. yoelii* epitope (3), did not have any significant effect on the levels of *P. yoelii* rRNA (Fig. 2A).

We also tested the effect on *P. yoelii* of the CTL clone CS.C7 which *in vivo* is protective against *P. berghei* sporozoites. As shown in Fig. 2B, the transfer of 2.5×10^7 cells results in partial decrease (40%) of the liver stage rRNA of *P. yoelii*. This partial inhibition may be due to the fact that CS.C7, differently from CS.B83, recognizes not only the *P. berghei* but also the *P. yoelii* peptide 277–288 *in vitro* (Fig. 1E). It is noteworthy that the inhibitory effect of the cross-reactive clone CS.C7 is much less efficient than the one mediated by the anti-*P. yoelii* clone YA26. The later clone (YA26), reduced by 85% the parasite rRNA when 5×10^6 , i.e. five times less cells, were transferred (Fig. 2B).

The capacity of clone YA26 to inhibit the development of liver stages was found to be dose-dependent. Reduction of the rRNA by 50% could be achieved after transferring as few as 2.5×10^6 cells, while none or very low levels of parasite rRNA were consistently observed after the adoptive transfer of




Fig. 2. *In vivo* inhibition of liver stage development by adoptively transferred CTL clones. 2.5×10^7 cells of various anti-*P. yoelii* (YA26, YB8, and YA15) and anti-*P. berghei* (CS.B83 and CS.C7) CTL clones were adoptively transferred to naive mice 6 h before challenge with *P. yoelii* sporozoites. The amount of *P. yoelii* rRNA present in the liver of infected mice was measured 42 h after challenge. The bars represent the mean value obtained from three mice \pm standard error of the mean (SE). The asterisk at YA26, in B, indicates that 5×10^6 cells were transferred to each mouse. Absence of parasite rRNA, as determined in this assay, means less than 1 ng in the sample.

1.2×10^7 of these cells. No inhibition of parasite development was seen upon transfer of 1×10^5 cells of this clone (Fig. 3).

Antibodies against murine IFN- γ and TNF fail to neutralize the anti-plasmodial activity of these CD8⁺ T cell clones

Earlier studies had shown that IFN- γ has a potent inhibitory effect on the development of the liver stages of malaria parasites (14). Furthermore it has been reported that neutralizing anti-IFN- γ antibodies can reverse the immunity induced by immunization with irradiated sporozoites (15). To determine whether IFN- γ plays an important role in the *in vivo* anti-liver stage activity of the CTL clones, the neutralizing anti-IFN- γ monoclonal antibody DB-1 was




Fig. 3. Dose dependence of the inhibitory activity of the CTL clone YA26 *in vivo*. Shown are the number of T cells adoptively transferred to naive mice, 6 h before their infection with *P. yoelii* sporozoites. The percentage inhibition was calculated in relation to the amount of parasite rRNA present in the liver of control mice, challenged with sporozoites but not injected with T cells. The bars represent the mean value obtained from three mice \pm SE. 100% inhibition signifies that the sample contained less than 1 ng of parasite rRNA.




Fig. 4. Neutralizing antibodies to murine IFN- γ and TNF fail to reverse the *in vivo* inhibitory effect of a CTL clone. Monoclonal antibodies to murine IFN- γ (0.5 mg/mouse) or TNF (0.3 mg/mouse) were injected into naive mice, 2 h before they received the CTL clone YA26 (7.5×10^6 cells per mouse). 6 h later, the animals were challenged with *P. yoelii* sporozoites. The percentage inhibition was calculated as in Fig. 3.

injected into mice, as previously described (15), prior to the adoptive transfer of the CTL clone YA26. The dose of antibody administered in different experiments ranged between 0.5 to 1.0 mg per mouse. As seen in Fig. 4, the degree of inhibition of parasite development mediated just by the injection of clone YA26 did not differ significantly from that seen in mice which had, in addition, been injected with the IFN- γ neutralizing antibody. We were also unable to reverse the protective activity of clone YA26 by injecting monoclonal antibody TN3.19.12 (0.3–1.0 mg per mouse) which is specific for and inhibits the biological activity of murine TNF *in vivo* (16). Furthermore, the inhibitory activity of this CTL clone was not reversed when the mice simultaneously received both of these monoclonal antibodies (data not shown).

Discussion

The present study demonstrates that adoptive transfer, into naive mice, of certain CD8⁺ CTL clones which recognize a defined epitope in the CS protein of *P. yoelii*, protects against sporozoite-induced malaria. These results resemble those obtained earlier in the *P. berghei* system (3), and thus confirm the more general validity of the protective role of anti-CS CD8⁺ CTL in sporozoite-induced rodent malaria.

The experiments described in the present report also demonstrate that the anti-parasite activity of these protective T cell clones is species specific. In fact, the results show that while certain anti-*P. berghei* and anti-*P. yoelii* CD8⁺ clones confer a high degrees of protection against sporozoites of the respective species, the same clones induce no or only a small inhibitory effect when the mice are challenged with sporozoites of the heterologous species.

Still, it is noteworthy that parasitemia did not develop in 20% of the mice which had received the anti-*P. yoelii* CTL clone YA26 and were challenged with *P. berghei* sporozoites (Table 3). In view of the fact that clone YA26 does not appear to cross-react *in vitro* with a synthetic peptide containing the *P. berghei* epitope, the partial cross-protection we observed suggests that this clone may possibly mediate a certain 'non-specific' inhibition of liver stage development. Alternatively, it is possible that clone YA26 cross-reacts *in vivo* with an epitope presented upon processing by the parasitized liver cells, which may differ somewhat in size and therefore in sequence from the peptide we used in the *in vitro* assay (17,18).

The most likely targets of the inhibitory effects of these cytotoxic T cells are the liver stages of the parasite. This view is based on the high degree of protection observed upon transfer of protective T cell clones 3 h after challenge, at a time when sporozoite invasion of hepatocytes is certain to have been completed (13). It is further corroborated by the fact that transfer of these clones did not protect mice against a challenge with blood stages of the same parasite. Furthermore, recent studies have shown that sporozoite-immune spleen cells, stimulated with a synthetic peptide comprising the *P. yoelii* 281–296 epitope, inhibit the development of *P. yoelii* liver stages in cultured mouse hepatocytes (5).

In the present report we demonstrate that the transfer of protective cytotoxic clones greatly reduces the level of parasite rRNA, thus providing direct evidence of the fact that these CD8⁺ T cell clones inhibit, in a dose-dependent manner, the

in vivo development of the liver stages of this parasite. Significant decrease of rRNA was seen upon transfer of only 2.5×10^6 cells of the YA26 clone. This is noteworthy since only a fraction of these cells reach the liver, most transferred cells being entrapped in the lung. Migration studies performed during a 48-h period with radiolabeled YA26 cells revealed that the amount of T cells which migrate to the liver reaches a maximum 24 h after transfer and represents $17.8 \pm 5.1\%$ of the total amount of transferred cells. The pattern of migration is not altered by a concurrent sporozoite infection (manuscript in preparation).

The individual anti-*P. yoelii* CD8⁺ T cell clones we assayed differed in their capacity to confer protection against a sporozoite challenge, resembling our earlier observations in the *P. berghei* system (3). These functional differences among CTL clones were highlighted in experiments in which the protective effect of the different clones was determined by measuring the parasite rRNA in the liver of the challenged mice. Parasite rRNA was undetectable (less than 1 ng per sample) and therefore reduced by more than 20-fold in the livers of mice injected with the protective clone YA26. The fact that parasite rRNA was not detectable under these conditions cannot be interpreted as indicating the complete absence of parasites in the liver, namely that sterile immunity has been achieved. The lack of detection of parasite rRNA under these conditions most likely reflects the limit of sensitivity of the assay (11).

Mice injected with clone YA15 had parasite rRNA levels similar to those found in control mice injected with sporozoites but not with CTL clones. These results were unexpected, in view of the results of the *in vitro* cytotoxic assays in which clone YA15 lysed target cells as efficiently as clone YA26, and produced similar or even larger amounts of IFN- γ . These findings indicate that the capacity of CTL clones to induce protection upon passive transfer requires *additional properties*, besides *in vitro* cytotoxicity.

Based on earlier studies (19), mice which had been injected with CTL clones, and their controls, were also injected with recombinant IL-2. Experiments in which we measured *P. yoelii* rRNA revealed that the administration of IL-2 did not alter the protective nor the non-protective effects of the transfer of clones YA26 and YA15, respectively (data not shown).

We are currently undertaking a detailed characterization of the fine epitope-specificity of these clones, of their profile of lymphokine production, and their patterns of migration and homing in mice. This will, hopefully, clarify the basis of the observed functional differences and cross-reactivities.

The mechanisms of the inhibitory activity of cytotoxic CD8⁺ T cell clones on the liver stages of malaria parasites has not yet been identified. It is possible that these clones exert a direct cytotoxic effect on the parasitized hepatocytes. Another possibility is that this inhibitory effect may be mediated by lymphokines produced locally by the CTL clones, after recognizing the corresponding epitope on the surface membrane of antigen-presenting cells (Kupffer cells or other mononuclear phagocytes).

It was reported earlier that IFN- γ and TNF inhibit the development of plasmodial liver stages *in vitro* (14,20). *In vivo* treatment of sporozoite-immunized A/J mice with anti-IFN- γ monoclonal antibody was reported to reverse protection against *P. berghei* sporozoites (15). However, a similar treatment of sporozoite-immunized BALB/c mice appears to have no detectable effect (21). Our current results regarding the unchanged *in vivo* anti-parasitic activity of these CTL clones, upon

administration of neutralizing anti-IFN- γ and anti-TNF antibodies, suggest that systemic levels of these lymphokines may not play a significant role in the inhibitory effector mechanisms. These results do not rule out the possibility that these cytokines might be produced and acting locally, in the micro-environment of the CD8⁺ T cells and of the infected hepatocytes.

Taken together these results indicate that the rodent malaras provide a rather unique experimental model for the investigation of the effector mechanisms by which CD8⁺ T cells can prevent the development of non-viral intracellular pathogens. The elucidation of these protective mechanisms should benefit ongoing attempts to design an effective malaria vaccine.

Acknowledgements

The authors would like to thank Dr Victor Nussenzweig for stimulating discussions and critical review of the manuscript. We also thank Mrs Rita Altzuler, Frank Gagliardi, and Yi Zhao for excellent technical assistance. M.M.R. is supported by a fellowship from the Brazilian National Research Council F.Z. is a recipient of the Irma T.Hirschl Career Development Award. P.J.R. is supported by a fellowship from Hoffmann-LaRoche. This work was supported by grant AI-27458-02 from NIH and grant DPE-0453-A-00-5012-00 from the Agency of International Development.

Abbreviations

CTL	cytolytic T lymphocytes
CS	circumsporozoite
IFN	interferon
IL	interleukin
MHC	major histocompatibility complex
TNF	tumor necrosis factor

References

- Nussenzweig, V. and Nussenzweig, R. S. 1989. Rationale for the development of an engineered sporozoite malaria vaccine. *Adv. Immunol.* 45:283.
- Tsujii, M., Romero, P., Nussenzweig, R., and Zavala, F. 1990. CD4⁺ cytolytic T cell clone confers protection against murine malaria. *J. Exp. Med.* 172:1353.
- Romero, P., Maryanski, J., Corradin, G., Nussenzweig, R. S., Nussenzweig, V., and Zavala, F. 1989. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protects against malaria. *Nature* 341:323.
- Kumar, S., Miller, L. H., Quakyi, I. A., Keister, D. B., Houghton, R. A., Maloy, W. L., Moss, B., Berzofsky, J. A., and Good, M. 1988. Cytotoxic T cells specific for the circumsporozoite protein of *Plasmodium falciparum*. *Nature* 334:258.
- Weiss, W. R., Mellouk, S., Houghton, R. A., Sedegah, M., Kumar, S., Good, M., Berzofsky, J. A., Miller, L. H., and Hoffman, S. J. 1990. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malana infected hepatocytes. *J. Exp. Med.* 171:763.
- Romero, P., Maryanski, J., Cordey, A. S., Corradin, G., Nussenzweig, R. S., and Zavala, F. 1990. Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. *Immunol. Lett.* 25:27.
- Farrar, J. J., Fuller-Farrar, J., Simon, P. L., Hilliker, M. L., Stadler, B. M., and Farrar, W. L. 1980. Thymoma production of T cell growth factor (Interleukin 2). *J. Immunol.* 125:2555.
- Maryanski, J. L., Acolla, R. S., and Jordan, B. 1986. H-2 restricted recognition of cloned HLA class I gene products expressed in mouse cells. *J. Immunol.* 136:4340.
- Van Der Meide, P. H., Dubbeld, M., Vijverberg, K., Kos, T., and Schellekens, H. 1986. The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. *J. Gen. Virol.* 67:1059.
- Sheehan, K., Ruddle, N., and Schreiber, R. 1989. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factor. *J. Immunol.* 142:3884.
- Arreaza, G., Corredor, V., and Zavala, F. 1991. *Plasmodium yoelii*: quantification of exoerythrocytic stages based on the use of ribosomal RNA probes. *Exp. Parasitol.* 72:103.
- Chomczynski, P. and Sacchi, N. 1987. Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156.
- Shin, S. C., Vanderberg, J. P., and Terzakis, J. A. 1982. Direct infection of hepatocytes by sporozoites of *Plasmodium berghei*. *J. Protozool.* 29:448.
- Ferreira, A., Schofield, L., Enea, V., Schellenkens, H., van der Meide, P., Collins, W. E., Nussenzweig, R. S., and Nussenzweig, V. 1986. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-Interferon. *Science* 232:881.
- Schofield, L., Villaquiran, J., Ferreira, A., Schellenkens, H., Nussenzweig, R. S., and Nussenzweig, V. 1987. Interferon-gamma, CD8⁺ T cells and antibodies required for immunity to malaria sporozoites. *Nature* 330:664.
- Ruddle, N. H., Bergman, C. M., McGrath, K. M., Lingenheld, E. G., Grunnet, M. L., Padula, S. J., and Clark, R. B. 1990. An antibody of lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. *J. Exp. Med.* 172:1193.
- Van Bleek, G. M. and Nathanson, S. G. 1990. Isolation of endogenously processed immunodominant viral peptide from class 1 H-2K^b molecule. *Nature* 348:213.
- Röttschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J., Jung, G., and Rammensee, H.-G. 1990. Isolation and analysis of naturally processed viral peptide as recognized by cytotoxic T cells. *Nature* 348:252.
- Taylor, P. M. and Askonas, B. A. 1986. Influenza nucleoprotein specific cytotoxic T cell clones are protective *in vivo*. *Immunology* 58:417.
- Mazier, D., Renia, L., Nussler, A., Pied, S., Marussig, M., Goma, J., Grillot, D., Miltgen, F., Drapier, J. C., Corradin, G., Del Giudice, G., and Grau, G. E. 1990. Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells. *Immunol. Lett.* 25:65.
- Hoffman, S. L., Isenbarger, D., Long, G. W., Sedegah, M., Szarfman, A., Waters, L., Hollingdale, M. R., van der Meide, P. H., Finbloom, D. S., and Ballou, W. R. 1989. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. *Science* 244:1078.

